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Summary.-The therapeutic value of sequential hemi-body irradiation (HBI) as a
primary treatment for small-cell lung cancer (SCLC) was compared to 3-drug cyclic
chemotherapy (CC) in a group of 64 patients with early and advanced disease. Thirty
patients were randomized to receive sequential HBI and 34 to receive CC. All patients
received a local radiation boost to the primary lesion.
An overall response rate of 87°' was obtained in patients treated with sequential
HBI and 88% in patients treated with CC. In patients with early disease, the esti-
mated median survival was 43 weeks when treated with HBI and 42 weeks when
treated with CC, but in advanced disease the estimated median survival was 15 weeks
and 44 weeks respectively. Of the patients with an initial complete response, the
estimated median survival was 51 weeks for HBI and 62 weeks for CC.
From these observations we suggest that sequential HBI treatment technique
with local radiation boost is an efficient method of tumour control in patients with
early small-cell lung cancer.
SMALL-CELL LUNG CANCER (oat cell,
SCLC) is one of the most aggressive and
lethal tumours known. Patients with dis-
seminated untreated disease have a mean
survival time of 7 weeks (Green et al.,
1969). Spread is so rapid via lymph and
haematogeneous routes that - 65% of
cases (Alberto et al., 1976) present with
disseminated disease. Common sites of
metastasis are brain, liver and bone, with
20% of all patients (Ihde et al., 1979)
having positive marrow aspirations when
first seen. These distant metastases,
whether detectable at diagnosis ordevelop-
ing soon after are the primary cause of
treatment failuire. Therefore, for practical
purposes of treatment, SCLC may be
considered a systemic disease.
SCLC has a rapid doubling time of
30-45 days (Green et al., 1969; Salazar
et al., 1976) which makes it responsive to
chemotherapy and radiotherapy. Good
responses have been obtained using either
or both of these treatments.
Increasingly, high-dose chemotherapy
has been used as the treatmentofchoicefor
initial induction therapy. Complete respon-
ses (CR) have been recorded in as many as
740 (Cohen et al., 1.978) of limited-
(lisease patients. The CR rate for patients
with extensive disease has been reported
in the 15°, range (Feld et al., 1979).
The achievement of CR in SCLC
patients has been well documented as
increasing mnediani suirvival and (lisease-
free interval (Oldham & Greco, 1980;
Greco et al., 1978; Salazar & Creech, 1980;
Salazar et al., 1.976). Randomized studies
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are in progress to evaluate the use of
non-cross-resistant chemotherapy (Pender-
grass et al., 1980; Livingston & Mira,
1980; Vincent et al., 1980) or alternating
vs sequential chemotherapy to achieve
and maintain a complete response (Daniels
etal., 1980;Aisneretal., 1980).
The number of disease-free patients
2 years from the start of treatment
remains between 7 and 300o (Salazar &
Creech, 1.980). An effective consolidating
treatment may be necessary to convert
complete responders into cures. Unfortu-
nately, improved response rates have
paralleled increases in treatment-related
complications and deaths due to cumula-
tive and progressive toxicity (Greco et al.,
1978: Salazar & Creech, 1980: Glode
et al., 1980).
Hemi-body irradiation (HBI) has been
reported to be valuable in the treatment
of SCLC (Salazar et al., 1980; Urtasun
et al., 1980; Woods et al., 1981). The most
serious toxicity from this treatment is
diffuse interstitial radiation pneumonitis.
In 1978, the actuarial incidence of this
complication, using single radiation doses,
was found to range from 29% at 8 Gy
to 84% at doses of 10 Gy (Fryer et al.,
1978). However, a more recent study from
the same institution, using density-
corrected absolute lung doses has observed
an actuarial incidence of 500 at 8-2 Gy.
The peak incidence occurred 2-3 months
after irradiation (Van Dyk et al., 1981).
Therefore one of the dose-limiting factors
to the single dose of radiation to both
lungs is normal-lung tissue injury. Pre-
vious use of HBI has shown that if an
interval of 4-6 weeks is observed between
the upper and lower body regions, no
serious haemopoietic injury occurs, with
peripheral counts returning to normal in
less than 5 weeks (Salazar et al., 1978).
In 1978, we initiated a randomized
clinical study to assess the usefulness of
the sequential HBI technique in the
primary management of patients with all
stages of SCLC and compared it to
multiple-agent sequential systemic chemo-
therapy (C(C). Response rate, length of
16
remission and survival were used as end-
points.
METHODS AND MATERIALS
The study was started in December 1978
and completed in December 1980. It was con-
ducted in a centre that serves a population
of 1 3 million. All lung tumours arising in this
population are investigated by the same
physicians. who refer all their patients to the
centre. A pulmonary path-ologist assigned to
the study reviews and confirms all the
pathological slides. Only tumours considered
as small-cell anaplastic bronchogenic car-
cinomas were included. All patients were
treated by one radiation oncologist and one
medical oncologist. Ten to 14 days aftei
diagnosis and before randomization, we
stratified the patients into the following 2
groups:
1. early disease confined to one hemithorax
or spread to the hilar lymph nodes in the
ipsilateral and contralateral regions, and/
or ipsilateral supraclavicular regions, that
is to say any T with any N but MO, and
advanced disease (spread to lymph nodes
in the contralateral supraclavicular region
and/or evidence of distal soft-tissue, organ
or lymphatic metastases).
Patients were then randomized to receive
either CC or sequential HBI within the group
to Nhich they had been assigned. All were
treated with debulking local radiation to the
primary site. Patients with Karnofsky func-
tional status <500,/ or over 72 years old were
not eligible for the study. We calculated
survival and time to progression from the
first dav of treatment. At the time of
documented progression, we transferred the
patients to the opposite therapy arm. All
patients were kept in the study until death.
We considered a patient in complete
response (CR) when there was clinical evi-
dence of disappearance of all active tumour
for at least 4 weeks, including re-ossification
of all lvtic lesions in the skeleton and normal-
ization ofmarrow biopsy, ifinitially involved.
We did not perform bronchoscopies to docu-
ment CR. We considered a patient in partial
response (PR) when there Mwas evidence of
)500/ reduction in the product of the
largest perpendicular diameters of the lesion
chosen before treatment of the primary
indicator lesions, with no progression of the
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other lesions or new sites ofmalignant disease
for at least 4 weeks. In patients with liver
metastasis, normalization of the liver scan
and blood chemistries, with 3000 reduction
in the sums of measurement below the costal
margin (using the umbilicus and iliac crest
as body landmarks), had to be observed.
These reductions in tumour size were to last
at least 4 -weeks. We considered a patient in
relapse on
(a) appearance ofnew lesion,
(b) reappearance of old lesions in patients
with CR, and
(c) for patients in PR, an increase of >5000
in the sum of the products of the diam-
eters of all measured tumours over the
measurements at the time of maximum
response.
We staged all patients at the time of
entrance to the study with marrow biopsy,
bone scan, liver scan and mediastinal tomo-
graphy. This was repeated at the time of
suspicion of relapse and before crossover.
Treatment groups
Group 1- Cyclic chemotherapy (CC).
We treated patients with a combination of 3
agents in cycles of every 28 days. Cyclo-
phosphamide (700 mg/M2 i.v.) and CCNU
(70 mg/M2 orally) were administered on Day
1 of the cycle. Methotrexate (20 mg/M2
orally) was administered on Days 18 and 21.
This combination was considered at the
time (1978) to represent one of the best cur-
rent conventional systemic chemotherapies
(Hansen et al., 1976, 1977). At the completion
of the third cycle, the mediastinum and the
original site of the primary lesion mwere
irradiated to a total midplane dose of 45 Gy
in 20 fractions, in a total time of 4 weeks,
using parallel opposed-pair technique up to
35 Gy and then changing to oblique fields to
avoid reaching the tolerance of the spinal
cord. Gross non-responding metastatic dis-
ease was also irradiated at that time. Chemo-
therapy was re-instituted at the completion
of the local radiation, and continued until
either evidence of progression of the disease
or after 1 year disease-free.
Group 2-Sequential hemi-body irradiation
(HBI).-We treated the patients starting
with the upper half-body, using anterior
and posterior fields to a volume extending
from the top of the head to the level of the
umbilicus, with the patient lving alternately
prone and supine. A single midplane dose of
8 Gy was delivered with the normal lung
parenchyma shielded to receive 6 Gy cor-
rected for lung density. We used 6 MelV
photons produced by a linear accelerator at
a source-to-axis distance of 200 cm and at a
dose rate of 40 Gy/min using parallel and
opposed anterior and posterior fields. At 6
weeks from the upper HBI, provided that the
platelet counts were over 105 and the white-
cell counts over 3500, we proceeded to irradi-
ate the lower hemi-body (from the umbilicus
level down to the feet) delivering 8 Gy mid-
plane dose (calculated using the average body
thickness) using the same source and dose
rate as for the upper HBI. We admitted the
patients to hospital for 48 h for the upper
HBI procedure, and they were premedicated
with prochlorperazine (Stemetil) 20 mg by
mouth and diazepam (Valium) 20 mg by
mouth 2 h before irradiation. Three weeks
after the upper HBI. we proceeded to irradi-
ate all patients in the mediastinum and the
original site of the primary, delivering 35 Gy
midplane dose in 15 fractions and in total
time of 3 weeks, using parallel opposing-pair
technique and shielding the cord to receive
less than 30 Gy.
From March 1978 to August 1980 Mwe
entered 64 previously untreated patients into
the study (Table 1). All fulfilled the protocol
requirements. Seventeen patients were unable
to complete the treatment as per protocol.
Eight patients on CC had evidence of disease
progression before completing the initial 3
cycles of chemotherapy, and had to be trans-
fered to HBI. Five patients on HBI had
disease progression before completing the
lower HBI, and had to be transferred to CC.
Three patients on HBI developed diffuse
interstitial radiation pneumonitis, delaying
further treatments and dying of disease
progression. One patient on HBI refused to
proceed wNith the lowNer HBI.
Two patients on the study had sudden
deaths unrelated to the tumour or the treat-
ment (myocardial infarction and GI bleed-
ing) at 6 and 30 days from entrance to the
TABLE I. Small-cell anapla.stic carcinoma
of lung (early and advanced). Patient
accrual December 1978-December 1980
Entered the study
Unrelated cleaths while on treatment
Inadequately treate(d
Adequiately treatedl
64
17
45
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'rABLE I . Small-cell anaplastic lung can-
cer. Patient composition in the two arms
of the study
Total
Female
MA1ale
Mlean age
Karnofsky > 70
Karnofsky 50-70
Early (%O)
Advanced (0)
CC HBI
34 30
10 8
24 22
58-6 55
33 26
1 4
30 27
23 20
study. The results- were analysed both
including and excluding these 19 patients.
Table II shows group comparability according
to age, stage and Karnofsky functional
status. Whenever possible, necropsies were
performed to confirm patterns of failure,
patterns ofmetastatic disease. and treatment-
related tissue damage.
Patients with documented disease recur-
rence on the initial treatment arm were
transferred to the other treatment arm. With
progression of the disease after transfer they
were treated at the discretion of the attend-
ing physicians, but follom-up was continued
for statistical purposes.
Before entering into the study, tests of
normal liver function and renal function and
normal peripheral haematological values
were required. These procedures included
blood determinations ofalkaline phosphatase,
serum glutamic oxalacetic transaminase, bili-
rubin, blood urea nitrogen, creatinine, uric
acid, total and differential white cell count,
platelet count, haemoglobin and haematocrit.
All these tests were done every 4 weeks while
the patients were in the study. High serum
calcium and serum electrolyte imbalance were
corrected in all patients.
RESULTS
In the 30 patients with advanced and
early disease treated with sequential HBI,
we obtained an 870% overall response rate.
When the patients with incomplete treat-
ment are excluded the response rate was
100%. In the 34 patients with advanced
and early disease treated with CC we
obtained an 88% overall response. This
response rose to 100% when incompletely
treated patients were excluded (Table IV).
In those patients with early disease
TABLE III. Tunour response rates in the
two experimental arms excluding and
including the patients that were inade-
quately treated
Response status
Excluding incomplete
treatment
Complete
Partial
Overall
Including incomplete
treatment
Complete
Partial
Nil
Overall
Response rates
CC (Oo) HBI (%)
15/26 (58)
11/26 (42)
26/26 (100)
15/34 (44)
15/45 (44)
4/34 (12)
30/34 (88)
11/19 (58)
8/19 (42)
19/19 (100)
14/30 (47)
12/30 (40)
4/30 (13)
26/30 (87)
Response statuis
Early disease
Complete
Partial
Overall
Advanced disease
Complete
Partial
Overall
Response rate
CC (%) HBI (Oo)
8/19 (42)
9/19 (47)
17/19 (89)
7/15 (47)
6/15 (40)
13/15 (87)
11/17 (65)
5/17 (29)
16/17 (94)
3/13 (23)
7/13 (54)
10/13 (77)
treated with sequential HBI the overall
response rate was 9400; when treated with
CC, the overall. response rate was 89%
(Table V). In those patients with advanced
disease the overall response rate was 7700
when treated with sequential HBI and
87% when treated with CC.
There was a difference favouring CC in
the overall median length of remission
(234 days for CC vs 117 days for HBI) and
this difference was statistically significant
in patients with advanced disease (240
days for CC vs 70 days for HBI, P = 0 002,
log-rank test).
The overall (early and advanced dis-
ease) median survival for patients that
completed the prescribed sequential HBI
treatment (19) was 40 5 weeks and for
TABLE IV.-Tumour response rates in the
two experimental arms calculated separ-
ately for advanced and for early disease.
Tumour response recorded as such only if
lasting at least 4 weeks
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TABLE V. Small-cell anaplastic lung cancer, median survival analysed according to stage
and type of response
( (C HBI
Stage
Early
Aclvance(l
Overall
Response
Complete
Partial
Nil
Estimate
medlian
survival *
(days)
302
:307
:307
433
167
Not
estimate(1
* Kaplan-Aleier siurvival.
Total D)eadl Censore(l
1'9
15
:34
15
15
4
1:3
11
24
7
1:3
4
6
4
10
8
2
Estimated
inedian
survival*
((lays)
304
105
159
:355
103
Not
estimate(d
Total D)ead Censored
17
14
31
14
12
5
13
1:3
26
1(0)
12
4
4
I
5
4
I
TrABLE VI. Comparative toxicities in each
treatment arm
IPneumonitis
Initial
After transfer
Marrow toxicity
Life-threatening
Severe
1oclerate
After transfer
Life-threatening
Severe
Modtiate?
('C (°/) HBI (0°,)
(4/30) 1.3
O O
(01:34)
(0/34) ()
(16/34) 47
HBI-'( CC
(0/15) ()
(1/15) 6 6
(6/15) 40
D)efinition of marrowv toxicity:
WABC'
Life-threatening: 0-50(
Severe: 5(0-1000
Moderate 1000-3000
(0/30) 0
(1/30) 3
(4/30) 13
(C-(0HBl
(0/7) 0
(2/7) 28 5
(4/7) 57 -1
P'latelets
<2 x 104
2-5 x 104
a-1 0x 10(4
Haematological toxicity for HBI measured as the
lowest weekly bloodl count recordedc over 6 weeks
after completion of radiation. Pulmonary toxicity
assessed by monthly chest N-ray and physical
examination up to 6 months.
those that completed at least 3 cycles of
chemotherapy (26) was 48-5 weeks. The
error in estimating 2-year survival was
considered too large because of the few
patients, and this is not included in our
results. When assessing survival according
to stage (Table VI) there was a definite
difference in favouir of CC in the sub-
group of patients with advanced disease,
whether or not the patients that did not
complete the trea,tment were included in
the analysis. There was no statistically
significant difference in the median stir-
vival of the complete responders group of
patients treated with sequential HBI or
chemotherapy (51 weeks vs 62 weeks).
However, there was a statistical differ-
ence in favour of CC in the median sur-
vival of the partial responders (24 weeks
for CC vs 15 weeks for HBI, P= 0-05, log-
rank test).
We were able to switch treatments
during progression of the disease in 22
patients; 600% obtained a second remission
that lasted a median of 12 weeks. Of 15
patients that relapsed after sequential
HBI and weretransferredto CC, 8 obtaine(d
a second remission that lasted a median
of 18 weeks.
Non-fatal diffuse radiation interstitial
pneumonitis was seen in 13% of the
patients treated with upper HBI in the
initial primary treatment arm, with a
peak incidence averaging 6 weeks. All
4 cases were examined post mortem, and
the diagnosis was proven. There was no
diffuse pneumonitis in the patients
switched to HBI from CC. Marrow toxicity
was common with both CC and sequential
HBI. We found that the incidence of
marrow toxicity increased when the
patients that relapsed were switched to
the alternative treatment modality (Table
II). It was not life-threatening, but
mainly severe-moderate toxicity (see
Table VI for definition of marrow toxici-
ties). It was most noticeable in the
patients receiving sequiential HBI as a
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second treatment after relapsing fiom the
riemissioni induced by CC. All the HBI
patients had weekly peripheral-blood cell
counts for 5 weeks. The CC patients were
followed every 4 weeks and peripheral-
blood cell counts were done at that time.
The average nadir of white-cell and
platelet counts after tipper HBI occurred
at 21 days, and for the lower HBI at 25
(lays. Fortv-seven per cent of patients on
CC needed a delay or modification of
chemotherapy due to ma,rrow toxicity.
Extreme anorexia with >200% body-
wt loss was seen in 5/34 patients treated
with CC and in 8/30 patients treated with
HBI, necessitating intraparenteral hyper-
alimentation in all 5 patients in the CC
group and in 4/8 patients in the HBI
group. The commonest acute toxicity
after tipper HBI was severe vomiting,
nausea, increase in temperature, tachy-
cardia and hypotension that lasted for
4-6 h ,with complete recovery after 12 lh,
which was not seen during the lower HBI.
There was no instance of deaths related
primarily to opportunistic infections, with
no proven instances of mycoplasm, pneu-
inocystic carinii or other opportunistic
infections producing diffuse interstitial
pneumonitis. Five patients had severe
Gran-negative septicaemia, necessitating
aggressive treatment with antibiotics, all
of them while receiving treatments after
crossover for recurrence.
Recurrent disease in the form of brain
metastasis was observed in 8/30 patients
treated with upper HBI as a primary
treatment and in 11/34 patients treated
with CC, without prophylactic brain
irradiation. Necropsy examinations were
performecl in 20% of expired patients in
both treatment arms. All showed failure
to control the tumour at the primary
irradiated intrathoracic region, as well
as the distal metastases.
I)1SCUSSION
Although partial or complete tumour
responses are currently easily obtained in
patients w\Nith SCLC treated with svstemic
chemotherapy with or without local radia-
tion to the primary, the maintenance of
this remission for years, achieving eventui-
ally the same survival as the normal
population corrected for the same age, is
a much more diffcult task. This is partly
due to tumour resistance to drugs and
radiation and partlv to the inability to
maintain a chemotherapeutic regimen for
long because of normal-tissue toxicity,
particularly of the marrow.
We chose to investigate the efficacy of
wvide-field irradiation in this disease in the
hope that, if proved efficient, it could
eventually be used as a maintenance or
consolidating agent. To that end we
attempted to assess its therapeutic efficacy
(tumour response/toxicity) not only as a
single agent but also in a small group of
patients that received in their manage-
ment both CC and HBI (patients that were
switched to the alternate modality at
relapse).
We decided to compare its efficacy as a
single modality in previously untreated
patients with advanced or early disease,
so that a fair comparison could be made
with the same type ofpatients treated with
what was considered at the initiation of
the study in 1978, as the best current
conventional systemic chemotherapy
(Hansen et al., 1977).
The sequential HBI technique produeed
little inconvenience to the patient, since
it was administered in 1 day, and there
was no need for hospitalization except
with the upper HBJ, which necessitated
the patient being admitted to hospital
for 48 h, because of moderate to severe
acute GI and systemic symptoms such as
nausea, vomiting, fever, and tachycardia,
which usuallv lasted for 5-6 h. In our
experience the patient generally becomes
symptom-free and ready to begin normal
activity in 24 h. This, in addition to the
13% incidence of interstitial diffuse pneu-
monitis, could be i nproved in the future
by fractionating the total dose ofradiation
over several days.
As can be seen in 'rable VI, sequential
HBI as the primary treatment has
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acceptable marrow toxicity, but this
more than doubles when HBI is used after
CC. This does not preclude its use, but it
emphasizes the need for extreme caution
when planning to use this modality before
or after CC. It is important that a second
remission of 3-4 months was obtained in
60% of the patients that relapsed and
were switched to either HBI or CC. It
appears therefore feasible to use HBI
after several courses of systemic chemo-
therapy, provided there is a minimum
interval of 5-6 weeks for marrow recovery.
Using the overall rate and duration of
response and median survival as end-
points, we found no evidence to reject the
null hypothesis that CC and HBI are
equally effective. However, on further
analysis, considering subgroups ofpatients
with factors that are known to affect
prognosis, such as a stage, typeofresponse,
whether they completed treatment or
not, we have found that in advanced
disease and in patients with partial
responses the HBI method alone, without
prior chemotherapy, appeared to be less
efficient than CC alone. Furthermore,
the 13% incidence of non-fatal radiation
pneumonitis for the group of patients
treated with HBI could make CC prefer-
able. From the practical point of view,
HBI is less cumbersome and inconvenient
to the patient. Both the CC- and HBI-
treated patients have the same quality of
survival. The incidence of extreme anor-
exia with gross weight loss and generalized
weakness, necessitating frequent hospital
admissions for intraparenteral hyper-
alimentation, was the same for both
groups, as was the incidence of oppor-
tunistic infections. The pattern of treat-
ment failure was the same for both
treatment arms with all the necropsy
material showing evidence of disease at
the primary as well as distal metastatic
sites, suggesting that the "boosting" dose
of radiation to the local primary site was
insufficient.
When analysing sequential HBI in
combination with CC as a maintenance or
consolidating agent, it appears that the
patients able to receive both treatment
modalities and achieving a second remis-
sion live longer than the patients whose
treatment was not switched, though the
toxicity, particularly to marrow, increased
in incidence and severity. This could
partially be avoided by proceeding with
HBI soon after 3 cycles ofinduction CC.
From our observations we conclude that
although sequential HBI as a primary
method of treatment is generally as
efficient as CC for small-cell lung cancer,
the suboptimal response in patients with
advanced disease prompts us to recom-
mend its use as a consolidating or main-
tenance agent in combination with a more
effective chemotherapy regimen. At pres-
ent, in our centre the treatment for early
as well as advanced disease consists of
3 months induction of cyclophosphamide
(1000 mg/m2 i.v. on Day 1, Adriamycin
(45 mg/M2 i.v.) Day 2 and VP-16 (180
mg/m2 i.v.) Days 1-3, in 21-day cycles
with concomitant local chest irradiation
to a dose of 50 Gy in 25 fractions in a
total time of 51 weeks, followed by
consolidation fractionated HBI at 2-5 Gy
per fraction in 4 consecutive fractions
for a total of 10 Gy.
The combination of CC and HBI should
be considered with extreme care in view-
of the increased incidence of severe mar-
row toxicity. Although we have not seen
an increased incidence of diffuse inter-
stitial pneumonitis at the time of treat-
ment switch, we recommend extreme
caution, particularly when using HBI
with chemotherapeutic agents known to
produce additive effects in normal tissue
oftarget organs.
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